Clinical trials to treat CELsignia selected patients are underway

We are collaborating with pharmaceutical companies and leading cancer researchers

FACT 1: Collaborating with Genentech and NSABP 
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant AC-THP in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Function.

(NCT03412643/FB-12)

This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELsignia test.
   
FACT 2: Collaborating with Puma Biotechnology and West Cancer Center 
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Neratinib Followed by Weekly Paclitaxel and Carboplatin Plus Neratinib in Early Stage Triple-Negative Breast Cancer Patients Who Exhibit Enhanced HER2 Signaling by Live Cell HER2 Signaling Transduction Analysis.

(NCT03812393)

This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with a pan-HER signal inhibitor in patients with triple-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELsignia test.